Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT04989803

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Led by Kite, A Gilead Company · Updated on 2026-04-24

247

Participants Needed

18

Research Sites

431 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.

CONDITIONS

Official Title

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Relapsed and/or refractory B-cell lymphoma
  • At least one measurable lesion
  • Adequate organ and bone marrow function
  • Age 18 years or older
Not Eligible

You will not qualify if you...

  • History of chimeric antigen receptor (CAR) therapy or other genetically modified T cell therapy
  • History of malignancy other than nonmelanoma skin cancer or carcinoma in situ unless disease free and without anticancer therapy for at least 3 years
  • History of allogeneic stem cell transplant
  • Autologous stem cell transplant within 6 weeks before planned infusion
  • Uncontrolled infections or infections requiring intravenous antimicrobials
  • Known infection with HIV, hepatitis B (HBsAg positive), or hepatitis C (anti-HCV positive) unless viral load undetectable
  • Suspected or confirmed central nervous system lymphoma
  • History or presence of central nervous system disorder
  • History of significant cardiac disease within 6 months before enrollment
  • Primary immunodeficiency
  • History of autoimmune disease requiring systemic immunosuppression or systemic disease-modifying agents within last 90 days
  • Full thickness lymphoma involvement or concern for gastric or intestinal perforation
  • Pregnant or breastfeeding females of childbearing potential

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 18 locations

1

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States, 85234

Actively Recruiting

2

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Duarte, California, United States, 91010

Actively Recruiting

3

Stanford Cancer Institute

Stanford, California, United States, 94305

Actively Recruiting

4

Northside Hospital

Atlanta, Georgia, United States, 30342

Actively Recruiting

5

Midwestern Regional Medical Center, Inc.City of Hope Chicago

Park Ridge, Illinois, United States, 60068

Actively Recruiting

6

University of MD, Greenebaum Comprehensive Cancer Center

Baltimore, Maryland, United States, 21201

Actively Recruiting

7

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Actively Recruiting

8

Columbia University Irving Medical Center

New York, New York, United States, 10032

Actively Recruiting

9

University of Rochester Medical Center

Rochester, New York, United States, 14642

Actively Recruiting

10

The Ohio State University Wexner Medical Center - James Cancer Hospital

Columbus, Ohio, United States, 43210

Actively Recruiting

11

The University of Texas, MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

12

Virginia Oncology Associates

Norfolk, Virginia, United States, 23502

Actively Recruiting

13

Royal North Shore Hospital

St Leonards, New South Wales, Australia, 2065

Actively Recruiting

14

Concord Repatriation General Hospital

Sydney, New South Wales, Australia, 2139

Actively Recruiting

15

Epworth Healthcare

East Melbourne, Victoria, Australia, 3002

Actively Recruiting

16

Universitatsklinikum Wurzburg

Würzburg, Germany, 97080

Actively Recruiting

17

Academisch Medisch Centrum

Amsterdam, Netherlands, 1105 AZ

Actively Recruiting

18

King's College Hospital

London, United Kingdom, SE5 9RS

Completed

Loading map...

Research Team

M

Medical Information

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma | DecenTrialz